Fig A. Sensitivity analysis 1, excluding participants with health conditions already present before index infection (cardiovascular diseases, respiratory diseases, mental disorders, neurologic or sensory disorders, cancer, metabolic diseases, <i>n</i

Fig A. Sensitivity analysis 1, excluding participants with health conditions already present before index infection (cardiovascular diseases, respiratory diseases, mental disorders, neurologic or sensory disorders, cancer, metabolic diseases, <i>n</i> = 599) and cases with a possible alternative medical explanation of persisting symptoms (<i>n</i> = 41). Shown are means (geometric mean for Composite Autonomic Symptom Score 31 [COMPASS-31] and Trail making test part B [TMT-B]) of self-reported health outcomes and neurocognitive tests (with 95% CI) by case-control status at clinical examination in phase 2. Fig B. Sensitivity analysis 1, excluding participants with health conditions already present before index infection (cardiovascular diseases, respiratory diseases, mental disorders, neurologic or sensory disorders, cancer, metabolic diseases, <i>n</i> = 599) and cases with an alternative explanation of persisting symptoms (<i>n</i> = 41). Shown are cardiopulmonary function